

# **PLEASE NOTE**

This document, prepared by the <u>Legislative Counsel Office</u>, is an office consolidation of this regulation, current to March 31, 2007. It is intended for information and reference purposes only.

This document is *not* the official version of these regulations. The regulations and the amendments printed in the *Royal Gazette* should be consulted to determine the authoritative text of these regulations.

For more information concerning the history of these regulations, please see the *Table of Regulations*.

If you find any errors or omissions in this consolidation, please contact:

Legislative Counsel Office Tel: (902) 368-4291 Email: legislation@gov.pe.ca

## **CHAPTER P-5.2**

## PHARMACEUTICAL INFORMATION ACT

#### GENERAL REGULATIONS

Pursuant to subsections 2(3), 3(2) and 4(6) and section 6 of the Pharmaceutical Information Act Stats. P.E.I. 2000, c.18, Council made the following regulations:

#### **1.** (1) In these regulations

Definitions

- (a) "Act" means the Pharmaceutical Information Act Stats. P.E.I. Act 2000, c.18;
- (b) "billing number" means a billing number held by a health billing number professional which authorizes the health professional to claim compensation payments under the Health Services Payment Act R.S.P.E.I. 1988, Cap. H-2 for basic health services provided by the health professional to his or her patients:

- (c) "capacity" means, in respect of a person, the ability of the person to understand the medication information maintained in the Program pertaining to the person, and includes
  - (i) an understanding of how the information applies to that person,
  - (ii) the ability to communicate that understanding,
  - (iii) the ability to make decisions relevant to the use of and access to the information, and
  - (iv) an understanding of the consequences of those decisions;
- (d) "Committee" means the Advisory Committee appointed under Committee section 4 of the Act:
- (e) "participating prescriber" means a prescriber who is registered participating under section 14 as a participating prescriber.
- (2) In these regulations, a reference to a third party who is acting on a Third party person's behalf does not include a parent or a guardian of the person. (EC211/07)

## ADVISORY COMMITTEE

- 2. (1) Subject to subsection (2), the Committee shall meet three times Meetings each calendar year.
- (2) Where the Minister or the Director urgently requires the advice of Special meetings the Committee on a matter, the Committee shall, subject to subsection (4)

and as soon as possible after the referral of the matter, meet to review the matter and provide advice to the Minister or Director, as the case may be, in respect of the matter.

Duties

2

- (3) In addition to the duties set out in the Act, the Committee shall
  - (a) subject to subsection (4), review and provide advice on matters referred to the Committee by the Minister or the Director; and
  - (b) keep a record of
    - (i) its observations while monitoring the Program as required by the Act, and
    - (ii) any advice it provides in accordance with the Act and these regulations.

# Referral to professional body

- (4) On the referral of a matter by the Minister or the Director to the Committee for its review and advice, the Committee
  - (a) may refer the matter to the professional body that the Committee considers appropriate to conduct such review and provide such advice, if the Committee is satisfied that the professional body is better qualified or more able to conduct the review and provide the advice required; and
  - (b) shall subsequently review and provide advice on the matter, if the Minister or the Director advises the Committee that he or she has not received advice from the professional body within 90 days of the date that the matter was referred to the professional body. (EC211/07)

Chairperson

**3.** (1) The Committee shall, at its first meeting in each calendar year, elect a chairperson, from among its members, who shall preside at its meetings.

# Expenses and

- (2) A member of the Committee shall, when attending to the business of the Committee, be
  - (a) reimbursed for such expenses incurred by the member; and
- (b) paid such remuneration for the member's services, as the Minister considers appropriate.

Executive secretary

(3) The Director shall act as executive secretary to the Committee and carry out such duties as the Committee may establish.

Meetings

(4) Five members of the Committee shall constitute a quorum at a meeting of the Committee.

Minutes

(5) The Committee shall keep minutes of its meetings, which shall be signed by the chairperson after the minutes have been approved by the Committee. (EC211/07)

## DISCLOSURE OF INFORMATION IN THE PROGRAM IDENTIFYING A PERSON

4. (1) An application for the disclosure of information in the Program Application for that identifies a person may be made to the Director

disclosure to the person identified

- (a) by the person, if the person is 18 years of age or older and has capacity; or
- (b) on behalf of the person, by a parent or guardian of the person, if the person is a minor or lacks capacity.
- (2) An application for disclosure must be made by completing a copy Form of application of Form 1 of Schedule A and by submitting it to the Director, together with the prescribed fee.

(3) The Director shall, on receipt of an application made in accordance Disclosure with this section, disclose to the applicant the information in the Program that identifies the person in respect of whom the application is made. (EC211/07)

**5.** (1) Where information in the Program that is disclosed to an applicant Application to under section 4 is found by the applicant to be inaccurate or incomplete, the applicant may request a correction by completing a copy of Form 2 of Schedule A and by submitting it to the Director.

correct inaccuracies

- (2) Following a review of a request made in accordance with Decision subsection (1), and of any evidence submitted pertaining to it, the Director shall, as the Director considers appropriate,
  - (a) correct or complete the information in the Program; or
  - (b) add to the information a statement of disagreement regarding the request to correct the information.
- (3) A correction or completion of the information in the Program or a Amended statement of disagreement added to the information shall remain part of the information in the Program from that time forward. (EC211/07)

**6.** (1) For the purposes of clause 5(2)(b) of the Act and subsection 11(2) Consent to of these regulations, a person is deemed to consent to the disclosure of disclosure information in the Program identifying the person to a pharmacist, participating prescriber or other health professional where

- (a) the person, or a parent or guardian of the person acting on the person's behalf, requests
  - (i) that a prescription be filled for the person, or
  - (ii) that the person be given treatment;
- (b) the person, or a third party acting on the person's behalf, provides the pharmacist or participating prescriber with the person's personalized password; or

(c) a prescriber, acting on the request of the person, asks for a prescription to be filled for the person.

Third party requests for prescriptions

4

- (2) Where
  - (a) a person does not have a personalized password; and
  - (b) a third party acting on behalf of the person requests a prescription to be filled at a pharmacy,
- a pharmacist shall, before filling the prescription,
  - (c) obtain from the third party a written consent completed by the person; or
  - (d) attempt to contact the person by telephone to obtain the person's verbal consent. (EC211/07)

Application for personalized password

- **7.** (1) Where information in the Program identifies a person, an application for a personalized password that may be given to pharmacists and participating prescribers to allow them to access that information may be made
  - (a) by the person, if the person is 18 years of age or older and has the capacity to decide whether or not to provide the personalized password to a pharmacist or participating prescriber; or
  - (b) on behalf of the person, by a parent or guardian if the person is a minor or lacks the capacity to make the decision referred to in clause (a).

Form of application

(2) An application for a personalized password must be made by completing a copy of Form 3 of Schedule A and by submitting it to the Director.

Issuance of password

(3) The Director shall, on receipt of an application made in accordance with this section, issue to the applicant the personalized password requested. (EC211/07)

Sign

- **8.** Every pharmacist and participating prescriber shall post a sign, or ensure that a sign is posted, in the pharmacy or place of business in which the pharmacist or participating prescriber works that advises the public of
  - (a) the existence and purpose of the Program;
  - (b) the requirement for consent to disclosure;
  - (c) the circumstances described in subsection 6(1) under which a person is deemed to consent to sharing of information;
  - (d) the person's right to disclosure of information from the Program identifying the person and to apply for and obtain a personalized password; and
  - (e) the duty of the pharmacist or participating prescriber, when dispensing any drug, to record with the Program all prescribed information. (EC211/07)

#### PHARMACISTS AND PARTICIPATING PRESCRIBERS

9. Pharmacists shall, when dispensing any drug, record with the Program Information to be the following information: recorded

- (a) the pharmacist's ID number;
- (b) the pharmacy's ID number;
- (c) the date the drugs are dispensed;
- (d) the prescription number or transaction number;
- (e) the date the prescription is submitted;
- (f) the group code of the Provincial Drug Program;
- (g) the patient's ID number (provincial health number or other);
- (h) the patient's date of birth;
- (i) the patient's gender;
- (i) the code indicating a new or refill prescription;
- (k) the number of prescription refills authorized;
- (l) the drug identification number;
- (m) the quantity dispensed;
- (n) the estimated number of days the prescription is to last;
- (o) the prescriber's ID;
- (p) the intervention or exception code, if used;
- (q) the directions for use. (EC211/07)
- 10. Participating prescribers may record the following information with Information that may be recorded the Program:
  - (a) new prescriptions;
  - (b) dosage changes:
  - (c) prescriptions on hold or discontinued;
  - (d) resumed prescriptions. (EC211/07)
- 11. (1) A pharmacist or a participating prescriber shall not access Purposes of access information in the Program for any purpose other than to

to information permitted

- (a) dispense a drug;
- (b) counsel a patient with regard to the patient's drug therapy;
- (c) consult with a pharmacist or a prescriber with regard to the patient's drug therapy;
- (d) conduct a drug usage evaluation;
- (e) check for any of the following problems
  - (i) unintended or adverse drug interactions,
  - (ii) medication duplication, or
  - (iii) unusual dosages; or
- (f) determine whether a drug usage or prescription is inconsistent with accepted pharmacy or medical practice.
- (2) When carrying out a review of information in the Program that Consultation identifies a person, a pharmacist or a participating prescriber may, with the consent of the person, consult with other health professionals.

Notice of problems

- (3) Where, on receipt of a request to fill a prescription or before issuing a prescription, a pharmacist or participating prescriber discovers a problem referred to in clause 11(1)(e) or (f) during a review of information in the Program that identifies the person, the pharmacist or participating prescriber shall, as soon as possible,
  - (a) take such action as is consistent with the best practice of pharmacy or medicine, including altering the dose, changing the drug or refusing to fill the prescription; and
  - (b) advise the person of the problem
    - (i) verbally, where the person is present,
    - (ii) by telephone or registered letter, or
    - (iii) by a sealed, written disclosure provided with any prescription filled for the person. (EC211/07)

Security measures

- **12.** (1) Every pharmacist in charge of a pharmacy and every participating prescriber shall ensure that the pharmacy or the place of business of the participating prescriber has security measures sufficient to prevent the unauthorized collection, retention, maintenance, alteration, use or disclosure of information in the Program, including ensuring that
  - (a) the computer terminal capable of accessing and displaying information in the Program is installed in such a way as to be inaccessible to anyone other than a pharmacist or participating prescriber and designated support staff;
  - (b) the terminal is under the supervision of a pharmacist or participating prescriber; and
  - (c) confidentiality undertakings, as set out in Form 4 of Schedule A, are completed and signed by
    - (i) any support staff in the pharmacy or place of business who are permitted to have access to the Program,
    - (ii) any software vendor representative who does business with the pharmacy or place of business, and
    - (iii) the owner or chief signing officer of the pharmacy or place of business.

Submission of Form 5

(2) Every pharmacist in charge of a pharmacy and every participating prescriber shall, before he or she first accesses information in the Program, complete and submit a copy of Form 5 of Schedule A to the Director. (EC211/07)

Emergency access to Program information 13. (1) Nothing in these regulations is to be construed as limiting or prohibiting access to information in the Program by a health practitioner acting in an emergency situation pursuant to clause 5(4)(a) of the Act.

Government employees

(2) Pursuant to clauses 2(2)(c) and 5(4)(b) of the Act, information in the Program is accessible by government employees in administering

government drug-benefit plans and programs, only to the extent that the information accessed pertains to those plans or programs.

(3) Pursuant to clause 5(4)(c) of the Act, information in the Program Information systems may also be accessed by employees and contractors responsible for the staff technical support and maintenance of the information systems used in the Program, only where the access pertains to work being carried out on the Program. (EC211/07)

Cap. P-5.2

#### PARTICIPATING PRESCRIBERS

14. (1) The Minister may, on application by a prescriber, approve the Registration registration of the prescriber as a participating prescriber if

requirements

- (a) the application is made in a form acceptable to the Minister; and
- (b) the Minister is satisfied that the prescriber
  - (i) has an active billing number, and
  - (ii) is a member in good standing of the prescriber's professional
- (2) The Director shall maintain a register of participating prescribers Register and shall

(a) enter in the register the name and address of a prescriber whose registration has been approved by the Minister; and

(b) remove from the register the name and address of a prescriber who is suspended or excluded by the Minister from participation in and access to the Program. (EC211/07)

## REPORTS, PLANNING AND RESEARCH

15. (1) Any person who wishes to make an application for the disclosure Reports, planning or of information in the Program shall submit to the Director

research

- (a) a completed copy of
  - (i) Form 6 of Schedule A, if the disclosure is requested for the purpose of planning or the preparation of a report, or
  - (ii) Form 7 of Schedule A, if the disclosure is requested for the purpose of research; and
- (b) the prescribed fees.
- (2) On receipt of the application for disclosure and the prescribed fees, Recommendation the Director shall review the application and shall recommendations to the Minister either for or against disclosure.

(3) The Minister may, when deciding whether to permit the disclosure Consolidation of requested, consider the Director's recommendations.

recommendations

(4) After making a decision in respect of a request for disclosure, the Decisions Minister shall give

- (a) the applicant a written notice of the decision; and
- (b) the Director a copy of the notice. (EC211/07)

#### **FEES**

Fees

**16.** (1) The fees prescribed for the purposes of these regulations are those set out in Schedule C.

Reduction

(2) The Minister may reduce the fees referred to in subsection (1) where a reduction is requested by an applicant who is a federal, provincial or territorial government body, an academic institution, or a student. (EC211/07)

#### COMPLAINTS, SUSPENSIONS AND EXCLUSIONS

Complaint inquiry

**17.** The Minister is vested with the powers of a commission under the *Public Inquiries Act* R.S.P.E.I. 1988, Cap. P- 31 and shall be deemed to have been appointed under that Act and to have been commissioned to cause inquiry into those matters or complaints that concern the Program and those matters that are within the powers of the Minister under the Act. (EC211/07)

# Suspension or exclusion

- **18.** (1) After
  - (a) causing inquiry into a matter or complaint pursuant to section 17; and
  - (b) considering the findings of the inquiry,

the Minister may suspend or exclude a pharmacist or participating prescriber from participating in and having access to the Program, if the Minister is satisfied that there is just cause for either such action.

Just cause

- (2) The following constitute just cause for suspending or excluding, under subsection (1), a pharmacist or participating prescriber from participating in and having access to the Program:
  - (a) any access to information in the Program sought for a purpose other than those permitted under subsection 11(1);
  - (b) any use of information in the Program for advertising;
  - (c) any intentional input into the Program of false or incorrect information;
  - (d) any improper prescribing or dispensing practice for which a pharmacist or participating prescriber is disciplined by his or her professional regulating body;
  - (e) any illegal act involving the prescribing or use of pharmaceuticals;
  - (f) anything else deemed as just cause by the Minister.

(3) A suspension or exclusion imposed under subsection (1) may be temporary or permanent.

Temporary or permanent suspension or exclusion

Cap. P-5.2

- (4) The Minister shall, before imposing a suspension or exclusion on a *Idem* pharmacist or participating prescriber,
  - (a) advise the professional body of the pharmacist or participating prescriber of the findings of the inquiry conducted in respect of the pharmacist or participating prescriber; and
  - (b) request and consider any recommendation made by the professional body of the pharmacist or participating prescriber respecting the duration of the suspension or exclusion. (EC211/07)
- **19.** (1) Subject to subsection (2), these regulations come into force on Commencement March 31, 2007.
- (2) Sections 8 and 9 of these regulations come into force on January 1, 2008.

# SCHEDULE A

## Form 1

Pharmaceutical Information Program PO Box 2000, Charlottetown, PEI C1A 7N8	Application for Disclosure to Individual Form 1	
Personal information on this form is collected under the <i>Pharmaceutical Information Act</i> and Regulations. This information is required in order to process your application for disclosure of information. If you have any questions about this collection of personal information, you may contact the Director of the Pharmaceutical Information Program.		
Name (Last name, given name)	Provincial Health Number	
Mailing address	Date of birth Gender	
Province Postal code	day / month / year	
Telephone number	Current PhIP password (if applicable)	
Identification (attach copy)		
□ birth certificate □ drivers license	(other)	
If history is required for person other than applicant: Parent/Guardian's name Telephone number		
Mailing address		
□ attach proof of guardianship		
I am requesting:		
<ul> <li>medication history, including the generic drug name, strength, dosage form, quantity, date filled, pharmacy, prescriber for the following calendar year(s)</li> </ul>		
access history, including date of access, name of pharmacy, pharmacist, prescriber for the following calendar years		
I understand the information requested above will be sent to me in the mail.		
Date	Signature	
For Office Use Only		
☐ fee paid calendar years @ \$10 per year = \$		

11

# Form 2

Pharmaceutical Information Act General Regulations

Pharmaceutical Information Program PO Box 2000, Charlottetown, PEI C1A 7N8			
	Pharmaceutical Information Act and Regulations. This information is required two any questions about this collection of personal information, you may contact		
Name (Last name, given name)	Provincial Health Number		
Mailing address  Province Postal code	Date of birth Gender  day / month / year   male   female		
Telephone number  Current PhIP password (if applicable)			
Identification (attach copy)  ☐ birth certificate ☐ drivers license			
If corrections are required for person other than applicant: Parent/Guardian's name  Telephone Number  Mailing address			
Corrections/Additions requested:			
Date Name of prescriber/pharmacy	Change requested Reason for change		
□ medication history attached □ additional changes attached			
I am requesting the listed corrections be made to my medication history. I understand this will require the Pharmaceutical Information Program to review the changes I am requesting and I give permission to the Pharmaceutical Information Program to contact me and my prescribers, pharmacies, and pharmacists, as needed, to verify the requested corrections.			
Date	Signature		

# Form 3

Pharmaceutical Information Program PO Box 2000, Charlottetown, PE1 C1A 7N8	Application for Password		
	Form 3		
Personal information on this form is collected under the <i>Pharmaceutical Information Act</i> and Regulations. This information is required in order to process your application for a password. If you have any questions about this collection of personal information, you may contact the Director of the Pharmacutical Information Program.			
Name (Last name, given name)	Provincial Health Number		
Mailing address	Date of birth Gender		
Province Postal code	day / month / year		
Telephone number	Current PhIP password (if applicable)		
Identification (attach copy)	Requested PhIP Password (numbers only)		
□ birth certificate □ drivers license			
(other)			
	(minimum 4 numbers, maximum 6 numbers)		
If password is required for person other than applicant: Parent/Guardian's name Telephone Number			
Mailing address			
attach proof of guardianship	☐ attach proof of guardianship		
I understand that once my password is assigned, no pharmacist or prescriber will be able to view my medication history unless I personally provide this password. The effect of this password is that pharmacists and participating prescribers to whom I have not provided my password cannot see my medication history. This also means that pharmacists or participating prescribers may refuse service without the password.			
I understand that if I forget my password, I must reapply for a new password. However, I understand that I cannot apply for a password more often than four times per month.			
I understand my password can be overridden in an emergency.			
Date	Signature		

## Form 4

Pharmaceutical Information Program PO Box 2000, Charlottetown, PEI C1A 7N8	Confidentiality Undertaking		
Personal information on this form is collected under the <i>Pharmaceutical Information Act</i> and Regulations. This information is required to fulfill the confidentiality requirements of the Act and regulations. If you have any questions about this collection of personal information, you may contact the Director of the Pharmacutical Information Program.			
Name (Last name, given name) Position:			
Mailing address			
Province Postal code	Telephone number		
I will not access or use any clinical or patient information in PhIP for any purpose other than those authorized by the <i>Pharmaceutical Information Act</i> and its regulations.  I agree at all times to treat as confidential the information in PhIP and will not participate in or permit the unauthorized release or disclosure of this information.  I agree to adhere to all legislation, policies, procedures and standards issued by PhIP related to the confidentiality, privacy and security of PhIP information.  I understand that the penalty upon conviction for any violation of the <i>Pharmaceutical Information Act</i> or regulations is a fine which may range from a minimum of \$15,000.00 to a maximum of \$50,000.00.			
Signature			

# Form 5

Pharmaceutical Information Program PO Box 2000, Charlottetown, PEI C1A 7N8	Confirmation of Confidentiality Undertaking		
Personal information on this form is collected under the <i>Pharmaceutical Information Act</i> and Regulations. This information is required to fulfill the confidentiality requirements of the Act and regulations, If you have any questions about this collection of personal information, you may contact the Director of the Pharmaceutical Information Program.			
Name (Last name, given name)	Position:		
Mailing Address			
Province Postal code	Telephone number		
alteration, use or disclosure of Program information, accessing and displaying Program information is inac staff.  I will not access or use any clinical or patient information Pharmaceutical Information Act and the regulation I agree at all times to treat as confidential information release or disclosure of this information.	revent the unauthorized collection, retention, maintenance, including ensuring that the computer terminal capable of eccessible to anyone other than myself and designated support ation in PhIP for any purpose other than those authorized by ons.  In in PhIP and will not participate in or permit the unauthorized es and standards issued by PhIP related to the confidentiality,		
As Pharmacist in charge, I have retained in my office confidentiality undertakings signed by a of the following:  • designated support staff • software vendor representative • Pharmacy owner/Chief Signing Officer The computer terminal(s) capable of displayin Program information is/are under the supervisof a pharmacist.	my office confidentiality undertakings signed by all of the following:  • designated support staff  • software vendor representative The computer terminal(s) capable of displaying Program information is/are under my		
Date	Signature		

Cap. P-5.2

## \_

Form 6

Pharmaceutical Information Program PO Box 2000, Charlottetown, PEI C1A 7N8		Application for Release of Information for Purpose of Reports or Planning Form 6	
Personal information on this form is collecte in order to process your application for relea collection of personal information, you may	se of informati	on for purposes of reports or planning.	If you have any questions about this
Individual(s) preparing report:			
Name	Position	Department	Institution
Mailing address of principal applicant:		Tel:	
			Fax:
Province Postal code			Email:
Title of project:		Type of project:	
			☐ standard report
			planning
Start date for project:		Completion date for project:	
Summary of project:			
proposal attached (max. 10 pages) Freq	uency of repo	ort: reports per	(example: week / month / year)
			Page 1 of 2



Pharmaceutical Information Program
PO Box 2000, Charlottetown, PEI

# Application for

CIA 7N8	Release of Information for Purpose of Reports or Planning Form 6
Specific data required: (include data fields and	date ranges)
Measures to protect confidentiality of data: (i	nelude who will have access, where stored)
Will PhIP data be linked or used in conjunction  no yes, source:	with data from other sources?
I understand the data can only be released in minimum of 20 individuals.     I understand the data can only be used for the	n aggregate, non-identifiable format, with all data cells containing a the project described above. Any additional use will require a new
application.  I agree at all times, to treat as confidential the lensure that by the project's completion day shredding paper records, and deleting electronic limits are supported by the lensure that by the project's completion day.	te all non-aggregated PhIP information will be destroyed, including ronic files and backups.
Date	Signature
For office use only:	or use of PhIP data

Page 2 of 2

17

## Form 7

Pharmaceutical Information Act General Regulations

	C1A 7N8 Relea		Release of	Application for ase of Information Research Purposes	
Personal information on this form is collected under the <i>Pharmaceutical Information Act</i> and Regulations. This information is required in order to process your application for release of information for research purposes. If you have any questions about this collection of personal information, you may contact the Director of the Pharmacutical Information Program.					
Principal	investigators:				
Name		Position	Department	Institution	
Mailing address of principal applicant:			Tel:		
				Fax:	
Province Postal code		Email:			
Title of pr					
Start date for project:		Completion date for project:			
Summary of project:					
□ propos	al attached (max. 10 pages)				
Research	Ethics Board (REB)	REB name (	see Schedule B):		
Su	abmission date:				
Status of review: ☐ pending ☐ approved ☐ denied					
Date			Signature		
				Page 1 of 2	

	Pharmaceutical Information Program PO Box 2000, Charlottetown, PEI C1A 7N8	Application for Release of Information for Research Purposes
Specific d	ata required: (include data fields and da	ite ranges)
Measures	to protect confidentiality of data: (incl	ude who will have access, where stored)
	data be linked or used in conjunction wit 1 yes, source:	h data from other sources?
I understand the data can only be released in aggregate, non-identifiable format, with all data cells containing a minimum of 20 individuals.  I understand the data can only be used for the project described above. Any additional use will require a new application.  I agree at all times, to treat as confidential the PhIP information received.  I ensure that by the project's completion date all non-aggregated PhIP information will be destroyed, including shredding paper records, and deleting electronic files and backups.  I will provide PhIP with a copy of the study results by the project completion date.		
Date		Signature
For office		use of PhIP data

(EC211/07)

Page 2 of 2

19

#### **SCHEDULE B**

Pharmaceutical Information Act

General Regulations

## **Acceptable Research Ethics Boards** For Applications on Form 7

University of Prince Edward Island Research Ethics Board Dalhousie Health Sciences Human Research Ethics Board Capital Health Research Ethics Board (QEII Health Sciences Centre) University of New Brunswick Research Ethics Board Memorial University of Newfoundland Research Ethics Board Comité d'éthique de l'Université de Laval McGill University Health Centre Research Ethics Board Queen's University General Research Ethics Board McMaster University Medical Research Ethics Board University of Toronto Health Sciences I Research Ethics Board University of Waterloo Human Research Ethics Committee University of Manitoba Health Research Ethics Board University of Saskatchewan Biomedical Research Ethics Board University of Alberta Health Research Ethics Board University of British Columbia Research Ethics Board

20

## **SCHEDULE C**

#### **Fees**

- 1. The fee payable for an application under section 4 for disclosure is \$10.00 per calendar year of information requested.
- 2. No fee is payable in respect of a request under section 5 to correct information.
- 3. No fee is payable for an application under section 7 for a personalized password.
- 4. The fees payable for an application under section 15 for the disclosure of information are as follows:
  - (a) a non-refundable \$400 administrative fee; and
  - (b) an analysis fee equal to the sum of
    - (i) the number of hours of staff time required to provide the information, multiplied by \$150, and
    - (ii) the number of records accessed, multiplied by 5 cents.